158 related articles for article (PubMed ID: 25240818)
1. Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma.
Farina L; Rezzonico F; Spina F; Dodero A; Mazzocchi A; Crippa F; Alessi A; Dalto S; Viviani S; Corradini P
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1982-8. PubMed ID: 25240818
[TBL] [Abstract][Full Text] [Related]
2. Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.
Viviani S; Mazzocchi A; Pavoni C; Taverna F; Rossi A; Patti C; Romano A; Trentin L; Sorasio R; Guidetti A; Gottardi D; Tarella C; Cimminiello M; Zanotti R; Farina L; Ferreri AJM; Galbiati M; Corradini P; Gianni AM; Gallamini A; Rambaldi A
Hematol Oncol; 2020 Oct; 38(4):501-508. PubMed ID: 32602970
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.
Weihrauch MR; Manzke O; Beyer M; Haverkamp H; Diehl V; Bohlen H; Wolf J; Schultze JL
Cancer Res; 2005 Jul; 65(13):5516-9. PubMed ID: 15994922
[TBL] [Abstract][Full Text] [Related]
4. Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma.
Guidetti A; Mazzocchi A; Miceli R; Paterno' E; Taverna F; Spina F; Crippa F; Farina L; Corradini P; Gianni AM; Viviani S
Leuk Res; 2017 Nov; 62():91-97. PubMed ID: 28992524
[TBL] [Abstract][Full Text] [Related]
5. Combined prognostic role of TARC and interim
Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
Hsi ED; Li H; Nixon AB; Schöder H; Bartlett NL; LeBlanc M; Smith S; Kahl BS; Leonard JP; Evens AM; Scott DW; Rimsza LM; Friedberg JW
Blood; 2019 Apr; 133(16):1762-1765. PubMed ID: 30723079
[TBL] [Abstract][Full Text] [Related]
7. CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma.
Cuccaro A; Annunziata S; Cupelli E; Martini M; Calcagni ML; Rufini V; Giachelia M; Bartolomei F; Galli E; D'Alò F; Voso MT; Leone G; Giordano A; Larocca LM; Hohaus S
Cancer Med; 2016 Mar; 5(3):398-406. PubMed ID: 26758564
[TBL] [Abstract][Full Text] [Related]
8. Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant.
Harrison SJ; Hsu AK; Neeson P; Younes A; Sureda A; Engert A; Prince HM; Li M; Savage P; Bugarini R; Williams D; Squier M; Ritchie DS
Leuk Lymphoma; 2014 May; 55(5):1053-60. PubMed ID: 23822537
[TBL] [Abstract][Full Text] [Related]
9. Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.
Bachanova V; Burns LJ; Ahn KW; Laport GG; Akpek G; Kharfan-Dabaja MA; Nishihori T; Agura E; Armand P; Jaglowski SM; Cairo MS; Cashen AF; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Ghosh N; Holmberg LA; Inwards DJ; Kanate AS; Lazarus HM; Malone AK; Munker R; Mussetti A; Norkin M; Prestidge TD; Rowe JM; Satwani P; Siddiqi T; Stiff PJ; William BM; Wirk B; Maloney DG; Smith SM; Sureda AM; Carreras J; Hamadani M;
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1605-11. PubMed ID: 25983043
[TBL] [Abstract][Full Text] [Related]
10. Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study.
Zijtregtop EAM; Diez C; Zwaan CM; Veening MA; Beishuizen A; Meyer-Wentrup FAG
Br J Haematol; 2023 Jan; 200(1):70-78. PubMed ID: 36128637
[TBL] [Abstract][Full Text] [Related]
11. TARC Predicts PET-Normalization and Event Free Survival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated With Brentuximab Vedotin.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):10-2. PubMed ID: 27007005
[No Abstract] [Full Text] [Related]
12. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP.
Driessen J; Kersten MJ; Visser L; van den Berg A; Tonino SH; Zijlstra JM; Lugtenburg PJ; Morschhauser F; Hutchings M; Amorim S; Gastinne T; Nijland M; Zwezerijnen GJC; Boellaard R; de Vet HCW; Arens AIJ; Valkema R; Liu RDK; Drees EEE; de Jong D; Plattel WJ; Diepstra A;
Leukemia; 2022 Dec; 36(12):2853-2862. PubMed ID: 36241696
[TBL] [Abstract][Full Text] [Related]
14. Serum measurement of thymus and activation-regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis.
Fujisawa T; Nagao M; Hiraguchi Y; Katsumata H; Nishimori H; Iguchi K; Kato Y; Higashiura M; Ogawauchi I; Tamaki K
Pediatr Allergy Immunol; 2009 Nov; 20(7):633-41. PubMed ID: 19236603
[TBL] [Abstract][Full Text] [Related]
15. Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience.
Roerden M; Sökler M; Kanz L; Bethge W; Vogel W; Walz JS
Ann Hematol; 2020 Feb; 99(2):265-276. PubMed ID: 31897675
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
17. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
[TBL] [Abstract][Full Text] [Related]
18. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma.
Sauer M; Plütschow A; Jachimowicz RD; Kleefisch D; Reiners KS; Ponader S; Engert A; von Strandmann EP
Am J Hematol; 2013 Feb; 88(2):113-5. PubMed ID: 23225085
[TBL] [Abstract][Full Text] [Related]
19. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.
Romano A; Parrinello NL; Vetro C; Forte S; Chiarenza A; Figuera A; Motta G; Palumbo GA; Ippolito M; Consoli U; Di Raimondo F
Br J Haematol; 2015 Mar; 168(5):689-700. PubMed ID: 25376846
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC.
Plattel WJ; Alsada ZN; van Imhoff GW; Diepstra A; van den Berg A; Visser L
Br J Haematol; 2016 Dec; 175(5):868-875. PubMed ID: 27610595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
